FUTURE

田纳西州梅哈里医学院（MMC）的癌症研究人员之间建立了牢固的联系， 州立大学（大津）和范德比尔特-英格拉姆癌症中心（VICC）导致这一正式的癌症 伙伴关系我们的伙伴关系致力于增强我们的优势，消除我们的弱点。 这三个机构，因为我们朝着我们的共同目标，消除癌症的差距在美国。U54 该奖项是这种合作的基石，并推动我们的合作研究更有力地走向 建立在互惠互利基础上的关系。这场竞争的总体目标是 更新申请是：（1）增加和稳定MMC的竞争性癌症研究能力， 大津;（2）在MMC、大津和VICC之间建立稳定、长期的癌症合作关系 研究、研究训练、职业发展及癌症外展服务;及（3）提高 VICC的研究、培训、职业发展、癌症教育和癌症外展活动， 旨在使维也纳国际中心所服务的区域内的少数群体受益。由U 54提供的资金将 巩固我们的合作。在我们的癌症伙伴关系的这一阶段，我们继续集中精力， 为癌症研究积累足够的基础设施，这将加强MMC、大津 和VICC。除了资助两个完整的项目和两个试点研究， 资金将用于为大津和维也纳国际中心招聘调查人员，并加强 通过核心设施的支持进行基础、流行病学和临床癌症研究， 生物统计学、临床试验累积、组织病理学和癌症外展。所有活动都涉及协调， MMC、大津和VICC之间计划良好的互动，并将由内部顾问监督 委员会由每个机构的成员组成，方案指导委员会由 外部，国家认可的癌症研究人员和国家癌症研究所的代表。一 持续和全面的癌症伙伴关系对三个参与机构有巨大的好处 以及美国中南部地区。该机构的互补优势将有助于巨蟹座 建立有效的癌症研究伙伴关系，增加两个少数民族服务的培训机会 机构，加强以社区和人口为基础的科学研究，针对少数民族癌症相关 在NCI资助的综合癌症中心，增加对少数民族科学家的培训。

Strong ties have developed between cancer researchers at Meharry Medical College (MMC), Tennessee State University (TSU) and Vanderbilt-lngram Cancer Center (VICC) resulting in this formal Cancer Partnership. Our Partnership is dedicated to enhancing the strengths and eliminating the weaknesses of our three institutions as we move toward our shared goal of eliminating cancer disparities in the US. The U54 award is the bedrock of this collaboration and has moved our collaborative research more forcefully toward a relationship that is based on reciprocity and stronger mutual benefit. The overall objectives of this competing renewal application are: (1) to increase and stabilize the competitive cancer research capability of MMC and TSU; (2) to create stable, long-term collaborative relationships between MMC, TSU and the VICC in cancer research, research training, career development and cancer outreach; and (3) to improve the effectiveness of VICC research, training, career development, cancer education and cancer outreach activities specifically designed to benefit minority populations in the region served by VICC. Funds provided by this U54 will solidify our collaboration. During this phase of our Cancer Partnership, we continue to concentrate on amassing sufficient infrastructure for cancer research that will strengthen reciprocity between MMC, TSU and VICC. In addition to funding two full projects and two pilot studies involving collaborators from all three institutions, funds will be used to recruit investigators to TSU and VICC and to strengthen infrastructure in basic, epidemiologic and clinical cancer research through the support of core facilities providing expertise in biostatistics, clinical trial accruals, histopathology and cancer outreach. All activities involve coordinated, well-planned interactions between MMC, TSU and VICC and will be monitored by an Internal Advisory Committee composed of members from each institution and a Program Steering Committee composed of external, nationally-recognized cancer investigators and representation from the National Cancer Institute. A sustained and comprehensive Cancer Partnership is of immense benefit to the three participating institutions as well as the mid-South region of the US. The institution's complementary strengths will help the Cancer Partnership establish effective cancer research and increase training opportunities at two minority-serving institutions, enhance community- and population-based science research targeting minority cancer-related disparities and increase training of minority scientists at an NCI-funded Comprehensive Cancer Center.